(MENAFN) Foremost Turkish pharmaceutical Abdi Ibrahim on September 18 declared that it had purchased 28.5 percent of the shares of Swiss-based biotech corporation OM Pharma for 4.2 billion liras (530 million USD).
A company statement showed that the attainment made Abdi Ibrahim the first and only Turkish pharmaceutical to outline a planned partnership with a European equivalent.
Nezih Barut the company chairman stated that "The partnership, and especially our biotech products, will facilitate our access to new markets, particularly Latin America, China, and the US,".
Similarly, OM Pharma, Barut added that will at the present have easier admission to the Middle East and North Africa, where Abdi Ibrahim enjoys a important attendance.
MENAFN2009202000450000ID1100825291
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.